Hormone therapy and venous thromboembolism
- 1 March 2003
- journal article
- review article
- Published by Elsevier in Best Practice & Research Clinical Endocrinology & Metabolism
- Vol. 17 (1) , 149-164
Abstract
No abstract availableKeywords
This publication has 98 references indexed in Scilit:
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Hormone replacement therapy in healthy postmenopausal women: a randomized, placebo-controlled study of effects on coagulation and fibrinolytic factorsJournal of Internal Medicine, 2001
- Comparison of effects of pravastatin and combined hormone replacement therapy on coagulation and fibrinolysisHeart, Lung and Circulation, 2000
- Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal WomenJAMA, 1998
- Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised womenThe Lancet, 1998
- Tamoxifen and risk of idiopathic venous thromboembolismBritish Journal of Clinical Pharmacology, 1998
- Effects of Hormone-Replacement Therapy on Fibrinolysis in Postmenopausal WomenNew England Journal of Medicine, 1997
- The effect of estrogen replacement therapy with or without progestogen on the fibrinolytic system and coagulation inhibitors in postmenopausal statusAmerican Journal of Obstetrics and Gynecology, 1995
- Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C.Journal of Clinical Investigation, 1994
- Oral contraceptives and venous thromboembolism: findings in a large prospective study.BMJ, 1986